Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Common Equity (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Common Equity data on record, last reported at $252.9 million in Q3 2025.

  • For Q3 2025, Common Equity fell 28.63% year-over-year to $252.9 million; the TTM value through Sep 2025 reached $252.9 million, down 28.63%, while the annual FY2024 figure was $337.2 million, 22.89% down from the prior year.
  • Common Equity reached $252.9 million in Q3 2025 per ZNTL's latest filing, down from $274.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $523.3 million in Q2 2023 and bottomed at $252.9 million in Q3 2025.
  • Average Common Equity over 4 years is $389.0 million, with a median of $385.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: increased 22.18% in 2023, then tumbled 35.61% in 2025.
  • A 4-year view of Common Equity shows it stood at $434.0 million in 2022, then grew by 0.75% to $437.3 million in 2023, then decreased by 22.89% to $337.2 million in 2024, then decreased by 25.0% to $252.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $252.9 million in Q3 2025, $274.5 million in Q2 2025, and $295.4 million in Q1 2025.